$MGX

$0.82 +$0.02 (2.71%) Close

$MGX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 37.8M shares outstanding

Who owns MGX?

By type of holder

Institutions 16.6% Insiders 9.6% Everyone else 73.8%

Concentration Top 10 holders own 19.9%

Thomas Brian C. 6.7% · Vanguard Capital Management LLC 2.9%

Institutional ownership

16.6%

-0.5 pts vs last qtr

Institutional holders

-5 vs last qtr

Net shares bought

−201.3K

by institutions in Q2 2026

New / sold out

4 / 9

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Wells Fargo & Company/mn +177.4K
Marquette Asset Management, LLC NEW +72.1K

Biggest sellers in Q2 2026

Jacobs Levy Equity Management, Inc −222.2K
Jane Street Group, LLC −113.0K

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Metagenomi Therapeutics Inc in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2023–FY2025

+994.1%

+230.78% a year

Each share's claim on the business

−90.9%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $35M

over 3 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years0% 1–3 years92% Under 1 year8%

Quarterly turnover

7.9%

of institutional shares changed hands

Top 10 managers, median time held

2.3 years

Super Investors

Investment managers reporting MGX on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
VC Vanguard Capital Management LLC	1.1M	2.85%	+19.8K (+1.9%)	2024	0.0%
Shares held by quarter Peak holding1.1M (Q2'26) Change over 8 quarters+1.1M Share of the company2.850% Vanguard Capital Management LLC's full portfolio →
RT Renaissance Technologies LLC	742.4K	1.97%	−45.5K (−5.8%)	2024	0.0%
Shares held by quarter Peak holding787.9K (Q1'26) Change over 8 quarters+560.3K Share of the company1.970% Renaissance Technologies LLC's full portfolio →

Vanguard Capital Management LLC

1.1M

% of company

2.85%

Change vs last qtr

+19.8K (+1.9%)

Held since

2024

Renaissance Technologies LLC

742.4K

% of company

1.97%

Change vs last qtr

−45.5K (−5.8%)

Held since

2024

28 more super investors behind a free account

See every manager holding Metagenomi Therapeutics Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting MGX on Form N-PORT; together they hold 4.8% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$882K	741.4K	1.96%	0.00%	June 30, 2026
UC Ultra-Small Company Fund Bridgeway Funds, Inc.	$438K	327.1K	0.87%	0.51%	March 31, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$882K

% of company

1.96%

% of the fund

0.00%

As of

June 30, 2026

Ultra-Small Company Fund

Bridgeway Funds, Inc.

Position value

$438K

% of company

0.87%

% of the fund

0.51%

As of

March 31, 2026

11 more funds behind a free account

See every fund holding Metagenomi Therapeutics Inc and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
TB Thomas Brian C. Insider	2.5M	6.65%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company6.650% Thomas Brian C.'s insider activity →
IJ Irish Jian Insider	668.1K	1.77%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company1.770% Irish Jian's insider activity →

Thomas Brian C.

Insider

2.5M

% of company

6.65%

Change vs last qtr

—

Held since

—

Irish Jian

Insider

668.1K

% of company

1.77%

Change vs last qtr

—

Held since

—

4 more holders behind a free account

See every insider and 5%+ holder of Metagenomi Therapeutics Inc.

Comments